Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Geldenhuys Werner J; Lin Li; Darvesh Altaf S; Sadana Prabodh

Drug Discovery Today

2017

2017-02

Although statins and other pharmacological approaches have improved the management of lipid abnormalities, there exists a need for newer treatment modalities especially for the management of hypertriglyceridemia. Lipoprotein lipase (LPL), by promoting hydrolytic cleavage of the triglyceride core of lipoproteins, is a crucial node in the management of plasma lipid levels. Although LPL expression and activity modulation is observed as a pleiotropic action of some the commonly used lipid lowering drugs, the deliberate development of drugs targeting LPL has not occurred yet. In this review, we present the biology of LPL, highlight the LPL modulation property of currently used drugs and review the novel emerging approaches to target LPL.

Animals; Cardiovascular Diseases/drug therapy/*enzymology; Humans; Lipoprotein Lipase/chemistry/*metabolism; Metabolic Diseases/drug therapy/*enzymology

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

352–365

2

22